Another Omi Rongzhu's new crown vaccine was clinically approved by the State Drug Administration

On July 7, 2022, the State Drug Administration officially approved the new coronary virus (hereinafter referred to as Aozhu) developed by the Chinese Pharmaceutical Group China Biological Wuhan Institute of Biological Products Research Institute. Safety and immunogenicity.

Since the outbreak of Omikon's mutation, Chinese creatures have immediately organized a research team in scientific research to launch research and development of Omikon vaccine. The Wuhan Biological Products Institute introduced the Omicor Rong mutant strains from the University of Hong Kong as soon as possible, using the hardware advantages of the three -level laboratory of the biological safety and high biological safety risk workshop and the technical advantages of the activation vaccine platform. Based on the development of new coronary virus in the plant, BETA plant, and Delta plant, quickly carried out scientific research research and developed Wibp-new coronary virus invasive vaccine (Ao strain). Cells are adsorbed by cultivation, survival, purification, and aluminum hydroxide agent.

On April 13, 2022, the vaccine was approved by the clinical trials of the Hong Kong Pharmacy and Poison Administration, which was officially approved to conduct clinical research in Hong Kong, China. On April 29th, the clinical trial approval of the Arab Emirates Abu Dhabi Health.

In the next step, the Wuhan Biological Products Research Institute will make every effort to promote the clinical research of the vaccine, and contribute to the early completion of clinical trials, formally put into use, and strive for the clock to defeat the new crown epidemic and ensure the safety of human public health.

Faced with the new crown epidemic, Wuhan Biological Products Research Institute carefully practiced the lofty mission of the country's epidemic prevention service services, and went together around the field of "diagnosis, cure, and prevention". A series of scientific and technological research work such as therapy and the research and development of the new crown -clone antibody drug. Among them, the treatment of new crown antibody treatment drugs such as Omikon and other mutant strains is actively applying for clinical trials to contribute to the global anti -new crown pneumonia epidemic.

Source: China Biological WeChat public account

- END -